Kyle Bass, the hedge fund manager vilified by the pharmaceutical industry and much of the patent bar, just gave his detractors more reason to resent him. The U.S. Patent and Trademark Office has agreed within the last week to institute trials for six of the drug patents Bass has challenged.
Earlier this month, the PTO’s Patent Trial and Appeal Board (PTAB) agreed to hear an additional pharma patent challenge filed by Bass through his Coalition for Affordable Drugs, bringing the total number of instituted challenges brought by the hedge fund manager to seven.
